Tabano Silvia, Azzollini Jacopo, Pesenti Chiara, Lovati Sara, Costanza Jole, Fontana Laura, Peissel Bernard, Miozzo Monica, Manoukian Siranoush
Medical Genetics, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milano, Italy.
Laboratory of Medical Genetics, IRCCS Ca' Granda, Ospedale Maggiore Policlinico Milano, 20122 Milano, Italy.
Cancers (Basel). 2020 Apr 8;12(4):910. doi: 10.3390/cancers12040910.
Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional and promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at testing. Quantitative and promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the promoter comparable with controls. Mean methylation levels (± stdev) at the promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively ( > 0.05; -test); mean methylation levels (± stdev) at the promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively ( > 0.05; -test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations.
先前关于乳腺癌和卵巢癌(BC和OC)的研究表明,构成性和启动子高甲基化作为表观遗传改变可导致肿瘤易感性。然而,这些基因上的表观突变的影响仍存在争议。对108名受BC、OC或两者影响且被认为携带种系突变风险非常高的女性进行了研究。所有样本在检测时均未发现致病变异或意义不明确的变异。通过Epityper质谱对外周血样本进行定量和启动子甲基化分析,并将结果与对照组进行比较。所有108例分析病例的启动子甲基化水平与对照组相当。对照组和患者启动子的平均甲基化水平(±标准差)分别为4.3%(±1.4%)和4.4%(±1.4%)(>0.05;t检验);对照组和患者启动子的平均甲基化水平(±标准差)分别为4.3%(±0.9%)和3.7%(±0.9%)(>0.05;t检验)。基于这些观察结果,对这些基因启动子的构成性甲基化分析似乎并不能显著改善对患者癌症风险的定义。这些数据支持了表观突变在高危BC/OC人群中是非常罕见事件的观点。